Based on a petition from UCB S.A. (OTCPK:UCBJF), the USPTO’s Patent Trial and Appeal Board (PTAB) will review the validity of Roche (OTCQX:RHHBY +0.4%) unit Genentech’s U.S. Patent No. 10,011,654 covering antibodies that target interleukin-17A, a proinflammatory cytokine.
The patent is part of a lawsuit that Genentech filed against Eli Lilly (LLY +0.2%)
last year claiming its entitlement to royalties on arthritis med Taltz
(ixekizumab), an IL-17A inhibitor. Lilly disagrees and has also filed a
petition with the PTAB.
https://seekingalpha.com/news/3504267-ucb-challenges-roche-patent-covering-ilminus-17-targeting-antibodies
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.